ARIAD Expands Leadership Team with Three New Appointments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of three senior executives to newly created positions on ARIAD’s leadership team: Matthew E. Ros as vice president, oncology marketing, Virginia R. Dean as vice president, human resources, and Frank G. Haluska, M.D., Ph.D. as senior medical director.
“We are extremely pleased to welcome these talented professionals to our leadership team”
“We are extremely pleased to welcome these talented professionals to our leadership team,” said Harvey J. Berger, M.D., chairman and chief executive officer. “They add substantial depth to our current management and demonstrate ARIAD’s long-standing commitment to building a world-class organization to execute on our strategy of becoming a fully-integrated oncology company.”
Matthew E. Ros
Vice President, Oncology Marketing
Mr. Ros will be responsible for planning and leading the U.S. launch of deforolimus with colleagues from Merck & Co., Inc. and preparing the market for ARIAD’s growing pipeline of oncology products, including its new multi-targeted kinase inhibitor, AP24534. He has an outstanding track record in the pharmaceutical industry with almost twenty years of experience in sales, marketing and operations management. Mr. Ros has held a series of senior positions at Bristol-Myers Squibb Company (BMS), most recently as Senior Director and U.S. Commercial Lead. He played a key role in the launch and commercialization of BMS’s most recent oncology products, ixabepilone (Ixempra™) and dasatinib (Sprycel®), as well as the early development of cetuximab (Erbitux®). Mr. Ros received his B.Sc. from the State University of New York.
Vice President, Human Resources
In this new role, Ms. Dean will help facilitate ARIAD’s anticipated growth and transformation from a research and development company to a fully integrated, commercially driven, oncology business. She brings almost fifteen years of experience in high-performing, rapidly growing organizations to ARIAD. Most recently, she was director, human resources at The Bridgespan Group, a professional services affiliate of Bain & Company, Inc. Ms. Dean’s background includes comprehensive human resource management, as well as the development and implementation of organizational development strategies. Her experience spans several industry sectors, such as professional services, software development, finance and non-profit consulting. Ms. Dean received her M.B.A. from the Simmons Graduate School of Management and her B.A. from the University of Vermont.
Frank G. Haluska, M.D., Ph.D.
Senior Medical Director
Dr. Haluska will be responsible for leading multiple clinical trials of oral deforolimus as part of the joint global development plan with ARIAD’s partner, Merck & Co., Inc. Dr. Haluska is a recognized authority on the targeted therapy of kinase abnormalities in solid tumors. Most recently, Dr. Haluska served as a senior faculty member in the departments of medicine and genetics at Tufts University School of Medicine, where he was Clinical Director and Deputy Director of the Tufts-New England Medical Center Cancer Center. He is also Major in the Medical Corps of the United States Air Force and the Massachusetts Air National Guard. Dr. Haluska brings to ARIAD fifteen years of experience in medical research and clinical oncology at centers of excellence, including the Dana-Farber Cancer Institute and Massachusetts General Hospital Cancer Center. He received his M.D. and Ph.D. from the University of Pennsylvania School of Medicine and his A.B. from Harvard University. He did postgraduate training at Massachusetts General Hospital, the Dana-Farber Cancer Institute and the Massachusetts Institute of Technology.
ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need – aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate. Medinol Ltd. and ICON Medical Corp. are also developing deforolimus-eluting stents to prevent restenosis of injured vessels following interventions in which stents are used in conjunction with balloon angioplasty. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB treatment methods, and the discovery and development of drugs to regulate NF-κB cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.
Ixempra, Sprycel and Erbitux are trademarks of Bristol-Myers Squibb Company.
This press release contains “forward-looking statements,” including statements related to the development and commercialization of ARIAD’s oncology product candidates. Forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the costs associated with our research, development, manufacturing and other activities, the conduct and results of pre-clinical and clinical studies of our product candidates, difficulties or delays in obtaining regulatory approvals to market products resulting from our development efforts, our reliance on our strategic partners and licensees and other key parties for the successful development, manufacturing and commercialization of products, the adequacy of our capital resources and the availability of additional funding, patent protection and third-party intellectual property claims relating to our and any partner's product candidates, the timing, scope, cost and outcome of legal and patent office proceedings concerning our NF-κB patent portfolio, the potential acquisition of or other strategic transaction regarding the minority stockholders' interests in our 80%-owned subsidiary, ARIAD Gene Therapeutics, Inc., future capital needs, key employees, markets, economic conditions, prices, reimbursement rates, competition and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.